It is recommended that blood cultures be performed on all patients admitted to the hospital with pneumonia. Questions regarding the cost-effectiveness of this practice have emerged. We used data on 13,043 Medicare patients hospitalized with pneumonia to determine predictors of bacteremia. Predictors included recent antibiotic treatment, liver disease and three vital sign and three laboratory abnormalities. Patients were stratified into three groups based on the likelihood of bacteremia. We then created a decision support tool which recommends performing no blood cultures on patients with low likelihood of bacteremia, one blood culture on patients with moderate likelihood of bacteremia, and two blood cultures on patients with higher likelihood of bacteremia. This tool was then applied to a validation cohort of 12,771 patients with pneumonia.
Approximately 1.1 million patients are hospitalized with pneumonia each year in the United States. 1 The reported frequency of bacteremia in these patients varies from as low as 4%
to as high as 14-18% in severely ill patients. 2, 3 Both the Infectious Diseases Society of America 4 and the American Thoracic Society 5 recommend that blood cultures be obtained from every patient hospitalized with pneumonia. In the current era of multi-resistant organisms, this practice may allow more effective antibiotic usage and surveillance of resistance rates. In addition,
performance of blood cultures on Medicare patients hospitalized with pneumonia has been associated with a lower mortality rate. 6 Blood cultures are also encouraged by the Centers for
Medicare & Medicaid Services in their quality improvement efforts. 7 Many investigators have questioned the need to obtain blood cultures from all patients hospitalized with pneumonia. 8, 9, 10, 11, 12, 13 Waterer et al 13 demonstrated that patients with a low risk of mortality, as defined by Fine's pneumonia severity index (PSI), 14 had a lower rate of bacteremia than patients with more severe disease. Others have noted the low yield of blood cultures, but nonetheless recommended them for all patients hospitalized with pneumonia. 15, 16 Chalasani et al noted that 4.8% of pneumonia patients had contaminated blood cultures, similar to the rate at which a pathogen was identified. 9 Contaminated blood cultures result in increased cost and excess hospital length of stay. 17, 18 Therefore if obtaining blood cultures from low-risk patients could be avoided, considerable cost savings might be realized.
We used a database containing detailed clinical information on Medicare patients admitted to the hospital with pneumonia to identify factors associated with bacteremia. A prediction tool was developed which accurately predicted the risk of bacteremia in a second cohort of patients with pneumonia. This tool could be used by clinicians to target patients in whom blood cultures are most likely to yield a pathogen. Some of the results of these studies have been previously presented in the form of an abstract.
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Methods
Sample Selection
Data analyzed in this study were part of the Medicare National Pneumonia Project, a component of CMS's Quality Improvement Program. Eligible patients were fee-for-service 
Statistical Analysis
Summary statistics were calculated for the abstracted data. Measures of association including univariate odds ratios and chi-square tests were performed. The relationship between bacteremia and demographics, medical comorbidity, physical examination, laboratory and radiographic variables as well as the PSI 14 were determined by univariate analysis. Variables associated with bacteremia with P<0.15 were used in a multivariate logistic regression analysis to determine which factors were independently associated with bacteremia (excluding contaminants). To identify the problem of collinearity, we calculated the phi coefficient of two dichotomous variables. 20 If two independent variables were highly correlated, the variable with the largest variance was excluded from the multivariate analysis. Logistic regression analysis was performed using the backwards elimination procedure. The goodness of fit of the model was tested with the Hosmer-Lemeshow test 21 which revealed adequate model fit (P =0.39).
Once we developed a prognostic model based on findings in the derivation cohort, we applied the model to the validation cohort to evaluate the predictive power of the model. Receiver operating characteristic (ROC) curves were constructed by a series of cut points from both the derivation and va lidation cohorts. 22 To test if the model prediction is better than chance prediction, we calculated the area under ROC curves (AUC) and their 95% confidence intervals (95% CI) for derivation cohort (AUC =0.68; 95% CI 0.66 -0.70) and validation cohort (AUC = 0.68; 95% CI 0.66 -0.70). 23 To test the reliability of the model, we compared the AUCs between the two cohorts (P =0.94).
All reported P values are based on two-tailed tests. Statistical significance was accepted at P<0.05. Analyses were conducted using the software packages Statistical Analysis System (SAS version 8.0, SAS Institute, Cary, NC). Receiver operating characteristic curve analysis was performed using AccuROC software (AccuROC version 2.5, Montreal, Quebec, Canada).
After validating the model, we created a prediction tool to define the risk of bacteremia, using clinical criteria that would be available to clinicians when the decision regarding blood cultures was being made. All variables which were independently associated with the presence of bacteremia with an odds ratio of greater than 1.3 were considered for inclusion in the tool.
Patients were stratified according to the number of predictive factors present and divided into three risk categories (low, moderate and high).
We then developed a decision support tool to select patients for blood culture performance, based on the estimated risk of bacteremia. An a priori assumption was that any predictive model would need to identify at least 85% of bacteremias to be clinically useful.
Because performing one blood culture resulted in a sensitivity for bacteremia of approximately 0.8 when compared to two blood cultures, we considered tools wherein we recommended only one blood culture for patients without a high risk of bacteremia. In these cases, the result of the first blood culture drawn was used to determine if the tool would have detected this patient's bacteremia. Thus, we designed a tool whereby the number of blood cultures collected was proportional to the risk of bacteremia.
Results
Patient Characteristics and Blood Culture Results
Of the 39,242 pneumonia cases in the 1998-99 sampling period, 16,327 (41.6%) were excluded from the primary analyses because no blood cultures were drawn during the 36 hours after presentation to the hospital. Of the remaining 22,915 cases, 5180 were excluded because of one of the general exclusion criteria, while another 4692 were excluded because of missing data elements (most commonly, the timing of blood cultures relative to initial antibiotics). Thus 13,043 cases were included in the derivation cohort. The initial sample size and frequency of exclusions were similar for the validation cohort. Demographic and clinical characteristics as well as outcomes were similar for each cohort (Table 1) .
Bacteremia was detected in 7% of the derivation cohort and 7% of the validation cohort, while 5% of all patients had at least one contaminated blood culture (Table 2) . Patients who had a contaminated blood culture had a longer hospital length of stay compared to patients with negative blood cultures, 7.7 ? 6.1 days versus days 6.6 ? 6.6 days, respectively, for the derivation cohort and 7.8 ? 10.7 days versus 6.5 ? 5.7 days, respectively, for the validation cohort (P<0.01
for both cohorts). Multivariate analysis revealed that much of this excess length of stay was attributable to the false positive blood culture (0.8 ? 0.3 days for the derivation cohort and 1.0 ? 0.3 days for the validation cohort). Patients with contaminated blood cultures were more frequently treated with vancomycin at some point during their hospital stay in both the derivation cohort (17% versus 6 %) and the validation cohort (19% versus 6%) (P<0.0001 for both cohorts). Table 3 shows the characteristics associated with bacteremia that were used in the prediction rule. The use of antibiotics prior to blood cultures, either before presentation or in the healthcare facility was negatively associated with the detection of bacteremia (OR, 0.5; 95%
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confidence interval, 0.5-0.6) Liver disease, three vital sign abnormalities and three laboratory abnormalities were found to be highly associated with bacteremia (Table 3) . Several variables not independently associated with bacteremia were noteworthy. These included age, and several variables relating to the degree of respiratory compromise, such as the presence of hypoxemia, pleural effusion or the number of lobes involved radiographically. A respiratory rate of 30 or above was associated with bacteremia, (OR, 1.3; 95% CI, 1.1-1.5, p=0.002), but not highly enough to be useful in the predictive model. The PSI was not significantly associated with bacteremia, when groups I, II and III were compared to groups IV and V (OR, 0.9; 95% CI, 0.7-1.1, p=0.2). Table 4 demonstrates that the risk of bacteremia could be predicted by assessing the prior use of antibiotics and the number of clinical predictors present. In the derivation cohort, 2% of the low-risk patients were bacteremic, 5% of the moderate-risk patients were bacteremic and 11% of the high-risk patients were bacteremic. Results were similar in the validation cohort. Table 5 demonstrates the number of bacteremic patients who would be detected by the prediction tool and number of blood cultures that would be avoided by its use. Use of the tool would have resulted in the detection of 88-89% of bacteremic patients, but would have required the performance of 37-38% fewer blood cultures. Among patients with the highest risk of mortality, those in PSI class V, use of the tool would have allowed detection of 94% of bacteremic patients in each cohort.
We calculated the performance of our prediction tool for patients less than 65 years of age and found its sensitivity among both cohorts for these younger patients was 89%.
We explored the performance of a simplified model that excluded the three laboratory predictors of bacteremia, as such a model might be easier to use in clinical practice. The decision support tool based on this model was optimized by the performance of one blood culture on all but the highest risk patients, for whom two blood cultures are recommended. This model identified 86-88% of bacteremic patients and decreased the number of blood cultures by 44% (Table 6 ). However, it only identified 89% of bacteremic PSI class V patients.
The pathogen-specific performance of the tool was also explored, with two noteworthy findings. The performance of the tool in detecting pneumococcal bacteremia was higher than its overall performance, as it detected 93% of pneumococcal bacteremias, but the tool was less sensitive for all other Streptococcus sp., detecting only 65% of bacteremias caused by these organisms.
Among the PSI class IV and V patients in both cohorts whose bacteremia was not detected by the use of this prediction tool, 30-day mortality (20%) was significantly lower than among all bacteremic patients in these risk classes (29%) (p<0.05). This suggests that those patients whose bacteremia was not detected by the prediction tool may have been "missed" because they were less seriously ill, despite being bacteremic.
We also examined the group of patients who were excluded from the primary analyses because they had no blood cultures. Sixty-one percent of patients without blood cultures were in PSI risk class IV or V, while 77% of patients who were cultured were in these risk classes. Our model predicted that 6% of those excluded from the derivation cohort were bacteremic, with similar results in the validation cohort. Because 42% of all patients with pneumonia were not cultured, it appears that with current clinical practice, about 38% of bacteremic patients with pneumonia do not have blood cultures performed.
Discussion
We have shown that several clinical variables were independently associated with bacteremia in a large cohort of patients admitted to the hospital with pneumonia. Using these predictors, we created a decision support tool that recommends not obtaining blood cultures from patients at low risk of bacteremia, obtaining one blood culture from moderate-risk patients and obtaining two blood cultures from high-risk patients. When applied to a second large cohort of pneumonia patients, this tool identified nearly 90% of all bacteremic patients and 94% of PSI class V patients, while allowing 38% fewer blood cultures to be drawn. Despite our finding of several clinical variable s that were highly associated with bacteremia, many non-bacteremic patients also had vital sign and laboratory abnormalities and this factor limited our ability to further restrict the recommended number of blood cultures.
Prior investigators have recommended that blood cultures not be performed on low risk patients with community-acquired pneumonia. 8 -13 Waterer et al found that by restricting blood cultures to PSI class IV and V patients, 56% of blood cultures could be avoided, but they would have failed to detect 29% of bacteremic patients. 13 In a cohort of 531 patients with communityacquired pneumonia, Roson et al found that only 67% of the bacteremic patients were in PSI class IV and V. 24 Campbell et al found little correlation between bacteremia and the PSI. 8 We found that the PSI was not an independent predictor of bacteremia. The superior performance of our model in predicting bacteremia is not surprising, as patient age is a major determinant of the PSI 14 and was not an independent risk factor for bacteremia.
What are the implications of failing to diagnose bacteremia in some patients with community-acquired pneumonia? Meehan et al found that the performance of blood cultures was associated with improved 30-day mortality among Medicare patients with pneumonia. 6 Our results also demonstrate that organisms other than S. pneumoniae caused over 60% of bacteremic community-acquired pneumonia, potentially increasing the risks of empiric therapy when the infecting pathogen is not identified. However, several studies have shown that even positive blood culture results usually do not result in adjustments of antibiotic therapy in patients with pneumonia. 8, 9, 11 It has also been reported that patients with pneumococcal bacteremia do not require a longer course of antibiotics than patients without bacteremia so that the identification of bacteremia may not be important for determining the length of therapy. 25 The potential risks incurred by the 11% false-negative rate associated with the use of our tool must be compared to the limitations of current practice. Forty-two percent of patients in the Medicare database were not cultured. Consequently, about 38% of bacteremic patients with pneumonia were not identified. Since this group of patients was less severely ill than the overall population with pneumonia, it seems that some clinicians decide to perform blood cultures based on clinical judgment regarding the severity of illness and/or the likelihood of bacteremia. The use of our tools could allow more accurate targeting of patients likely to be bacteremic.
Any potential risks associated with a decreased use of blood cultures must be balanced against the risks and costs of obtaining the approximately 10,000 cultures required to identify the approximately 100 bacteremias that were "missed" in each cohort. Given the 3.1% rate of resistance to this antibiotic. 26 We recommend the use of one blood culture for patients with a moderate risk of bacteremia. Although others have recommended the use of only one blood culture in certain populations, 27 many experts question the usefulness of one blood culture in any setting. 28 However, in a patient with a clinical presentation suggesting community-acquired pneumonia who has no indwelling intravascular devices, even a single blood culture growing an organism that commonly contaminates blood cultures should be easily identifiable as a contaminant, because none of these organisms cause pneumonia.
Our study has some limitations. There are clinical factors associated with bacteremia that were not measured. Examples might be injection drug use or physical exam evidence suggesting disseminated infection. In patients defined as low risk by our rule with clinical signs suggesting bacteremia, blood cultures should still be performed. Another potential limitation is that our database was derived from Medicare patients and may not be generalizable to younger patients.
However, patients below 65 years of age made up approximately 10% of each cohort and the prediction tool performed equally well for these patients. Also, the variables we used were dichotomous variables, and it is possible that a model using continuous variables may have yielded different results. Finally, while there would be indisputable benefits derived from reducing the total number of blood cultures drawn from patients with community-acquired pneumonia, there was a 20% mortality rate among bacteremic patients who would have been "missed" by this decision tool. We can not dismiss the possibility that these severely ill patients could be at increased risk if their bacteremia was not identified. Recent reports suggest that the magnitude of this risk may be small, given the lack of evidence of an affect on patient outcomes. 8, 10, 11 However, we must await further studies to determine whether outcomes would be optimized by striving to identify 100% of bacteremias or whether the appropriate balance of risk and benefit would be achieved by obtaining even fewer blood cultures and only identifying, for example, 75% of bacteremias.
There may be barriers to the adoption of these decision support tools in the clinical arena.
The use of laboratory values is a potential limitation to the use of the original tool, as this could delay the performance of blood cultures and hence the delivery of antibiotics. However, a common practice in Emergency Departments is to place an intravenous catheter and simultaneously draw routine laboratories and if appropriate, at least one set of blood cultures for febrile patients who appear as if they may require hospitalization. Furthermore, if laboratory results are not available, blood cultures can be obtained and the decision as to whether to send them for processing can be made once all of the necessary data is available. Of course, this 13 concern would not be a factor if the simplified tool were used, as it did not rely on laboratory data. Another practical matter that could affect the utilization of these tools is that many physicians may not make the effort to commit either of them to memory. While they are much simpler than the PSI, it is possible that they would not be extensively used unless incorporated into pneumonia management protocols with preprinted orders.
In summary, we found that several easily determinable clinical characteristics are independently associated with bacteremia in patients admitted to the hospital with pneumonia.
Using these characteristics, we developed a model that accurately predicted the likelihood of bacteremia at the time of presentation to the hospital. Two decision support tools based on this model were more sensitive than the PSI in predicting bacteremia. We suggest that the use of one of these tools would reduce the number of blood cultures performed on patients with communityacquired pneumonia , yet allow the identification of nearly 90% of bacteremic patients. Avoiding blood cultures in low-risk patients would minimize the excess cost and prolonged hospital length of stay associated with false-positive blood cultures. 
